SecBot SecBot
8-K/A ·Filed Nov 19, 2026

LSTA

LISATA THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed2d 15h ago SEC0001140361-26-044916
8-K with no item list reported
Actionable Insight • Neutral

The filing is a procedural amendment to provide pro forma financials for an S-3 registration statement. The massive dilution of legacy holders (2.4%) and deep operating losses of the combined entity are already known from the original merger announcement. Monitor the stockholder vote on the Series C conversion and any subsequent capital raises or clinical milestones for Marea's pipeline.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

This 8-K/A (Amendment No. 2) provides unaudited pro forma combined financial statements for Lisata Therapeutics following its acquisition of Marea Therapeutics on September 17, 2026. The pro forma statements show a combined net loss of $81.0 million for the nine months ended September 30, 2026 and $60.8 million for the year ended December 31, 2025, with legacy Lisata stockholders retaining only 2.4% of the combined company on a fully diluted basis. The filing is procedural, supplementing the original 8-K with required pro forma financials for a registration statement.

Key Facts

  • Lisata acquired Marea on September 17, 2026 for an estimated purchase price of $377.8 million, consisting of 1,793,129 common shares and 211,365.213 shares of Series C Preferred Stock.
  • A concurrent PIPE raised $225.0 million through the sale of 150,867.995 shares of Series C Preferred Stock at $1,491.37 per share.
  • Pro forma combined net loss was $81.0 million for the nine months ended September 30, 2026 and $60.8 million for the year ended December 31, 2025.
  • Pro forma basic and diluted net loss per share was $7.47 for the nine months ended September 30, 2026 and $5.80 for the year ended December 31, 2025.
  • On a fully diluted basis after stockholder approval, former Marea stockholders are expected to hold 59.5%, PIPE investors 38.1%, and legacy Lisata stockholders 2.4% of the combined company.
  • The preliminary purchase price allocation includes $292.9 million of in-process research and development (IPR&D) and $64.7 million of goodwill.
  • Marea raised $65.0 million in bridge financing via SAFEs prior to the merger, which converted into Marea common stock at $1.45 per share.

Financial Impact

Pro forma combined net loss of $81.0M for 9M 2026 and $60.8M for FY 2025; legacy Lisata stockholders diluted to 2.4% ownership on a fully diluted basis.

net lossdilutionrevenueoperating expensescash and cash equivalents

Risk Factors

  • Legacy Lisata stockholders face extreme dilution to 2.4% of the combined company on a fully diluted basis.
  • The combined company reported substantial operating losses ($102.3M for 9M 2026 pro forma) with no near-term revenue prospects.
  • The preliminary purchase price allocation is subject to change and could materially affect reported financials.
  • The Series C Preferred Stock carries a Cash Settlement Right that could require significant cash outflows if conversion is delayed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001140361-26-044916
Document: ef20085959_8ka.htm0001140361-26-044916
Document: 0001140361-26-044916-index-headers.html0001140361-26-044916
Document: 0001140361-26-044916-index.html0001140361-26-044916
Document: 0001140361-26-044916.txt0001140361-26-044916

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Viewing Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 19, 2026